Hyperhomocysteinemia and cardiovascular diseases - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Annales de Biologie Clinique Année : 2022

Hyperhomocysteinemia and cardiovascular diseases

Résumé

Homocysteine (Hcy) is a sulfhydryl-containing amino acid, which is not acquired through the diet, but rather synthesized as an intermediate metabolite in the methionine cycle. Hcy is present in plasma, with normal levels between 5 and 15 mu mol/L, a slightly elevated level between 15 to 30 mu mol/L, moderate from 30 to 100 mu mol/L and a value > 100 mu mol/L classified as severe hyperhomocysteinemia (HHcy). HHcy has been associated with inflammation and atherosclerosis and is considered an independent risk factor for cardiovascular diseases (CVD). Here, we review the main evidence showing the association and the possible involvement of HHcy in the most common CVD.
Fichier non déposé

Dates et versions

hal-03791830 , version 1 (29-09-2022)

Identifiants

Citer

Régis Guieu, Jean Ruf, Giovanna Mottola. Hyperhomocysteinemia and cardiovascular diseases. Annales de Biologie Clinique, 2022, 80 (1), pp.7-14. ⟨10.1684/abc.2021.1694⟩. ⟨hal-03791830⟩
28 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More